Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494110 | 0.94 | GAA (0.38) | GAAKMT2ATARDBPCYP1A2CYP3A4 | |
| SCHEMBL2449256 | 0.91 | ALDH1A1 (0.37) | GAAKMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL22266241 | 0.91 | TSHR (0.46) | GAAKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL22266272 | 0.91 | GAA (0.55) | GAAKMT2AMEN1TSHRKDM4E | |
| SCHEMBL6001519 | 0.89 | GAA (0.36) | GAA | |
| SCHEMBL22297101 | 0.89 | ALDH1A1 (0.48) | GAACES2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL20325130 | 0.89 | GAA (0.58) | GAACES2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8743883 | 0.89 | CES2 (0.50) | CES2KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2576358 | 0.88 | TP53 (0.35) | GAAKMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL22047274 | 0.88 | TP53 (0.35) | GAAKMT2ACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044636-A2 | NANOCLUSTERS FUNCTIONALIZED WITH ADENOSINE TRIPHOSPHATE OR AN ANALOGUE AND THEIR USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023164224-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2020219497-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3386520-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | The Regents of The University of California (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100470-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2011050342-A2 | RATIONAL DESIGN OF A BIOCOMPATIBLE SYNTHETIC LAMININ-111 POLYMER AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-5336621-A | Divalent hapten derivatives | HOECHST CELANESE CORPORATION (US) | 1994-08-09 | — | — | US | disclosed |
| EP-0183901-B1 | BIFUNCTIONAL HAPTENS, METHOD FOR THEIR PRODUCTION AND THEIR USE | BEHRINGWERKE Aktiengesellschaft (DE) | 1992-07-08 | — | — | EP | disclosed |
| US-4760142-A | Divalent hapten derivatives | HOECHST CELANESE CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0183901-A2 | Bifunctional haptens, method for their production and their use | BEHRINGWERKE Aktiengesellschaft (DE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | GAA 504/4885CES2 1466/4885KMT2A 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.